Advances in the Study of Marine Products with Lipid-Lowering Properties

• Main Authors: Jiarui Zhao, Qi Cao, Maochen Xing, Han Xiao, Zeyu Cheng, Shuliang Song, Aiguo Ji
• Format: Article
• Language: English
• Published: MDPI AG 2020-07-01
• Series: Marine Drugs
• Subjects: cardiovascular diseases; atherosclerosis; hyperlipidemia; hypolipidemic; marine products
• Online Access: https://www.mdpi.com/1660-3397/18/8/390

With twice the number of cancer’s deaths, cardiovascular diseases have become the leading cause of death worldwide. Atherosclerosis, in particular, is a progressive, chronic inflammatory cardiovascular disease caused by persistent damage to blood vessels due to elevated cholesterol levels and hyperlipidemia. This condition is characterized by an increase in serum cholesterol, triglycerides, and low-density lipoprotein, and a decrease in high-density lipoprotein. Although existing therapies with hypolipidemic effects can improve the living standards of patients with cardiovascular diseases, the drugs currently used in clinical practice have certain side effects, which insists on the need for the development of new types of drugs with lipid-lowering effects. Some marine-derived substances have proven hypolipidemic activities with fewer side effects and stand as a good alternative for drug development. Recently, there have been thousands of studies on substances with lipid-lowering properties of marine origin, and some are already implemented in clinical practice. Here, we summarize the active components of marine-derived products having a hypolipidemic effect. These active constituents according to their source are divided into algal, animal, plant and microbial and contribute to the development and utilization of marine medicinal products with hypolipidemic effects.